BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS), based in Alpine, Utah, announces a new peer-reviewed study published in Pediatric Critical Care Medicine on glycocalyx biomarkers in children with sepsis. In this study entitled “Endothelial and Glycocalyx Biomarkers in Children With Sepsis After One Bolus of Unbalanced or Balanced Crystalloids,” Jaime Fernández-Sarmiento and colleagues from Department of Pediatrics and Intensive Care, Fundación Cardioinfantil-Instituto de Cardiología, Universidad de La Sabana, Bogotá, Colombia, used the GlycoCheck™ system to test for the effect of different resuscitation fluids on the endothelial glycocalyx in children with sepsis and septic shock.

Findit, Inc., a Nevada Corporation (OTC PINK:FDIT), owner of Findit.com, a full-service social networking platform that provides tools for members to increase brand awareness through content creation and sharing, resulting in indexing in search engines, announce they have entered into a Definitive Agreement with BioRegenx, Inc. ("BioRegenx") The merger has been approved by each company's board of directors and is anticipated to close in the first quarter of 2023, subject to customary closing conditions including regulatory approvals. The merger will constitute a major change of control of the public entity to the executive team of BioRegenx. The name of the public entity will be changed to BioRegenx, Inc. and the newly merged company will apply for a new ticker symbol that relates to the new name.

BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS) based in Alpine, Utah, announces a new peer-reviewed study that reveals how individuals with obesity are at risk of developing cardiovascular disease. The study included the use of GlycoCheck™, a FDA registered Class 1 medical testing device. The paper is titled Microvascular Differences in Individuals With Obesity At Risk of Developing Cardiovascular Disease. The senior author is Dr. Hans Vink, the inventor of GlycoCheck™ and Chief Science Officer of BioRegenx. The objective was to investigate microvascular differences in individuals with obesity at risk for developing cardiovascular disease.

Microvascular Health Solutions, LLC (MVHS), a BioRegenx subsidiary based in Alpine, Utah, announces that a new peer-reviewed study has been published using GlycoCheck, a medical testing device, exclusively distributed worldwide by MVHS. The study, titled The microvascular endothelial glycocalyx: An additional piece of the puzzle in veterinary medicine, looked at the role of the endothelial glycocalyx in dogs and cats. The study was published by the The Veterinary Journal, and it was authored by researchers at the Bristol Veterinary School, University of Bristol, Bristol, UK.

BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS) based in Alpine, Utah, announces a new peer-reviewed study analyzing the impact of COVID-19 on children. The study included the use of GlycoCheck™, a FDA registered Class 1 medical testing device. The study of COVID-19 on children confirms how endothelial glycocalyx damage has been associated with severe inflammation, thrombotic phenomena, and profound hypoxemia in critically ill patients. The study, titled Case Report: Endothelial Glycocalyx Damage in Critically ill Patients With SARS-CoV-2-Related Multisystem Inflammatory Syndrome (MIS-C) reports that endothelial activation leads to a loss of the endothelium's antithrombotic properties which, under normal conditions, are maintained by the endothelial glycocalyx, the carbohydrate-rich layer that covers the luminal surface of endothelial cells. In children, one of the serious forms of SARS-CoV-2 virus disease (COVID-19) is multisystem inflammatory syndrome (MIS-C). This new disease is characterized by a large inflammatory response and frequent cardiovascular, cutaneous, and gastrointestinal disorders.

BioRegenx, Inc. and its subsidiary, Microvascular Health Solutions, LLC (MVHS) based in Alpine, Utah, announces a new peer-reviewed study on microvascular dysfunction in sepsis that included the use of GlycoCheck™, a FDA registered Class 1 medical testing device. The study, titled Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study was published in Critical Care. Critical Care is a peer-reviewed, international clinical medical journal that provides a comprehensive overview of the intensive care field. One of the co-authors of the study is Dr. Hans Vink, Chief Science Officer of BioRegenx.

BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS) based in Alpine, Utah, announces that a new peer-reviewed study has been published using GlycoCheckTM, a FDA registered Class 1 medical testing device, exclusively distributed worldwide by MVHS. The study, titled Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease, concludes that endothelial glycocalyx thickness is reduced in patients with psoriasis and is associated with impaired coronary and myocardial function, and vascular atherosclerosis. The study was published in the Journal of Human Hypertension by Dr. Ignatios Ikonomidis and his research team from National & Kapodistrian University of Athens and Attikon University Hospital in Athens, Greece.

BioRegenx, Inc. and its subsidiary Microvascular Health Solutions, LLC (MVHS), based in Alpine, Utah, announces that two peer-reviewed studies have been published using GlycoCheck, a medical testing device exclusively distributed worldwide by MVHS. Dr. Hans Vink, Chief Science Officer of BioRegenx, co-founder of GlycoCheck B.V. and the inventor of the GlycoCheck medical testing device, is one of the world’s leading researchers of endothelial glycocalyx health. Dr. Vink said “These papers confirm that for patients who have a damaged glycocalyx there is a correlation between microvascular health and cardiovascular health due to reduced capillary density.”